At a glance
ClinicalIndex Comparison RecordPhase 3Completed· 376 enrolled
Drug / intervention
LCZ696 +3 moredrug
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
A Randomized 8-week Double-blind, Parallel-group, Active-controlled, Multicenter Study to Evaluate Efficacy and Safety of LCZ696 200 mg in Comparison With Olmesartan 20 mg in Essential Hypertensive Patients Not Responsive to Olmesartan
In Brief
A Phase 3 clinical trial evaluating LCZ696, Olmesartan, and 2 other interventions for Hypertension. Completed, enrolled 376 participants across 51 sites in 7 countries.
Detailed Summary
This study will assess the efficacy and safety of LCZ696 in comparison to olmesartan in essential hypertensive patients not adequately responsive to olmesartan
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsHypertension
CountriesArgentina, Guatemala, Philippines, Puerto Rico, Russia, Spain, United States
Collaborators--
Timeline
Phase 3CompletedFinished
2014201520162017201820192020202120222023202420252026
First PostedJun 2013
Enrollment StartSep 2013
Primary CompletionAug 2014
TodayJul 2026
First PostedJun 12, 2013
Enrollment StartSep 1, 2013
Primary CompletionAug 1, 2014
TodayJul 2, 2026
Enrollment to primary: 11 monthsPosted 13.1 years ago
Interventions
LCZ696drug
Olmesartandrug
Placebo of LCZ696drug
Placebo of Olmesartandrug